Physician profile
Robert Gold
NPI 1639166820
$1,833.80
in general payments reported to CMS, 2019-2025
20 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $408 · 2021: $243 · 2022: $356 · 2023: $159 · 2024: $73.03 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $504.19 | 2019-2023 | Myrbetriq |
| Pfizer INC. | $279.43 | 2019-2023 | |
| Terumo Medical Corporation | $142.42 | 2022 | |
| Rochester Medical Corporation | $129.71 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.00 | 2021-2025 | |
| Janssen Biotech, INC. | $124.95 | 2019-2024 | Erleada |
| Baxter Healthcare | $115.47 | 2020 | |
| Olympus America INC. | $84.03 | 2019-2023 | Soltive |
| C. R. Bard, INC. & Subsidiaries | $68.23 | 2019 | |
| Neotract INC. | $53.75 | 2019 | |
| Boston Scientific Corporation | $43.43 | 2021-2022 | |
| Urogen Pharma, INC. | $23.46 | 2025 | |
| Tolmar, INC. | $19.82 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.64 | 2025 | |
| Sumitomo Pharma America, INC. | $17.71 | 2025 | Gemtesa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $17.55 | 2021 | |
| Davol INC. | $17.18 | 2024 | Arista Ah Flexitip |
| Laborie Medical Technologies Corp. | $15.54 | 2022 | |
| Amgen INC. | $14.83 | 2023 | Prolia |
| Endo Pharmaceuticals INC. | $13.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.